---

🐕 INFECTIOUS CANINE HEPATITIS (ICH) — Complete Veterinary Guide

---

📌 SECTION 1 — BASIC IDENTITY & CLASSIFICATION

What is ICH?

Virus Classification

Key Point: CAV-1 and CAV-2 are antigenically related, which is why CAV-2 vaccine protects against CAV-1 infection. This is the basis of modern vaccination.

---

📌 SECTION 2 — EPIDEMIOLOGY (Who Gets It?)

Host Range

• Primarily: Domestic dogs (Canis lupus familiaris)
• Wild canids: Wolves, foxes, coyotes, jackals
• Other species: Bears (Ursus arctos), raccoons — documented reservoir hosts

Age Susceptibility

• Most severe disease: Puppies under 1 year (especially < 6 months)
• Peracute/fatal forms: Most common in very young, unvaccinated pups
• Older dogs may show milder or subclinical infection if some immunity exists

Geographic Distribution

• Worldwide — all continents, but incidence has dramatically decreased in countries with widespread vaccination programs
• Outbreaks still occur in unvaccinated populations and wildlife

Risk Factors

• Unvaccinated or incompletely vaccinated dogs
• Kennels, shelters, breeding facilities (high density)
• Exposure to urine of recovered dogs (virus shed for 6+ months after recovery)
• Immunocompromised animals

---

📌 SECTION 3 — TRANSMISSION (How Does It Spread?)

Routes of Transmission

1. Oronasal route — most common; ingestion or inhalation of virus from:
   • Urine, feces, saliva, nasal discharge of infected dogs
   • Contaminated food bowls, bedding, hands of owners
2. Direct contact — dog-to-dog contact
3. Fomites — virus survives on surfaces, instruments, clothing
4. In utero transmission — rare but documented

Environmental Survival

• CAV-1 is non-enveloped, making it resistant to many common disinfectants
• Survives months in the environment at cool temperatures
• Effective disinfectants: Sodium hypochlorite (bleach, 1:30 dilution), quaternary ammonium compounds, iodophors, formaldehyde
• Resistant to: Lipid solvents (ether, chloroform), because it has no lipid envelope

Incubation Period

• 4–9 days after exposure

---

📌 SECTION 4 — PATHOGENESIS (Step-by-Step Mechanism)

Step 1 — Entry & Initial Replication

• Virus enters via the oronasal route
• Initial replication occurs in the tonsillar crypts and Peyer's patches (gut-associated lymphoid tissue) — this is the PRIMARY site of early viral replication

Step 2 — Primary Viremia

• Virus spreads from tonsils and gut to the bloodstream
• Carried by mononuclear cells to systemic circulation
• Primary viremia occurs 2–4 days after infection

Step 3 — Target Organ Infection (Key Pathology)

• Liver (hepatocytes + Kupffer cells) — massive centrilobular to midzonal necrosis
• Vascular endothelium — throughout the body — this causes the disseminated hemorrhages
• Kidneys (glomeruli and tubular epithelium)
• Spleen — white pulp necrosis
• Eyes (corneal endothelium)
• Brain (vascular endothelium) — in severe/neurological cases
• Lymph nodes — edema and hemorrhage

Step 4 — Hepatocellular Necrosis

• CAV-1 replicates within hepatocyte nuclei → forms intranuclear inclusion bodies (Cowdry Type A inclusions — large, eosinophilic, basophilic at early stage)
• Hepatocyte death → release of liver enzymes → ALT, AST, ALP all markedly elevated
• Necrosis pattern: centrilobular to midzonal (zone 3 of hepatic acinus)

Step 5 — Coagulopathy (DIC)

• Endothelial damage activates the coagulation cascade
• Liver damage impairs production of coagulation factors
• Result: Disseminated Intravascular Coagulation (DIC) — simultaneous clotting AND bleeding
• Clinically: petechiae, ecchymoses, prolonged clotting times, spontaneous bleeding

Step 6 — Immune Phase & "Blue Eye"

• As the dog mounts an immune response (antibodies appear ~7 days post-infection), immune complexes (antigen-antibody complexes) form
• These complexes deposit in:
  • Corneal endothelium → corneal edema → "Blue Eye" (hepatitis blue eye) — a unilateral or bilateral corneal opacity
  • Renal glomeruli → glomerulonephritis → protein loss in urine

"Blue Eye" (Corneal Edema):

• Occurs in ~25% of naturally infected dogs
• Can also occur as a vaccine reaction with old live CAV-1 vaccines (rare with modern CAV-2 vaccines)
• Usually transient (resolves in days to weeks)
• Occasionally permanent if severe

Step 7 — Resolution OR Death

• Mild/moderate cases: Antibodies neutralize virus, dog recovers but may shed virus for months
• Severe cases: Overwhelming hepatic necrosis → hepatic failure → death
• Chronic: Some dogs develop chronic active hepatitis or glomerulonephritis

---

📌 SECTION 5 — CLINICAL SIGNS (by severity)

Form 1: PERACUTE (Fulminating) — Most Severe

• Dog found dead with no premonitory signs
• OR: sudden collapse, seizures, severe hemorrhagic gastroenteritis
• Death within hours to 24 hours
• Seen mostly in puppies < 3 months old
• Mortality: near 100%

Form 2: ACUTE — Classic Presentation

• Sudden high fever (40–41°C / 104–106°F)
• Lethargy, depression, anorexia
• Tonsillitis (pharynx is very red/painful)
• Vomiting, diarrhea (sometimes hemorrhagic)
• Abdominal pain — dog may stand with elbows out ("praying" position / tucked abdomen)
• Bilateral conjunctivitis, photophobia, serous nasal discharge

• Marked jaundice (icterus) — yellow mucous membranes, skin, sclera
• Hepatomegaly (enlarged liver, detectable on palpation + pain)
• Ascites (fluid in abdomen) in severe cases

• Petechiae (pinpoint hemorrhages) on mucous membranes, skin
• Ecchymoses (bruising)
• Prolonged bleeding from venipuncture sites, cuts
• Hematuria, melena (blood in urine, black tarry stools)

• Seizures
• Ataxia (wobbly gait)
• Blindness (from central or corneal involvement)

• Develops during recovery phase (7–10 days)
• One or both eyes become blue-grey, cloudy
• Associated with photophobia and blepharospasm

Form 3: SUBACUTE / MILD

• Slight fever, mild lethargy, anorexia
• Mild conjunctivitis
• Dog recovers in 5–7 days without specific treatment
• May still shed virus for months

Form 4: SUBCLINICAL (Inapparent)

• No visible signs
• Dog seroconverts silently
• Acts as a carrier and source of infection for other dogs

---

📌 SECTION 6 — GROSS PATHOLOGY (Necropsy Findings)

Liver

• Hepatomegaly — enlarged, friable (easily crumbles)
• Enhanced lobular pattern visible on cut surface (due to centrilobular necrosis)
• Fibrin deposits on liver surface (serofibrinous peritonitis)
• Reddish-brown mottled appearance

Gallbladder — HALLMARK LESION ⭐

• Thickened, edematous gallbladder wall — this is a highly characteristic and pathognomonic finding in ICH
• Gallbladder edema can be so severe it resembles a tennis ball
• Hemorrhage in gallbladder wall

Hemorrhages — Widespread

• Petechiae and ecchymoses ("paintbrush hemorrhages") on:
  • Serosal surfaces (peritoneum, pleura)
  • Mucous membranes
  • Subcutaneous tissues
  • Brain surface

Lymph Nodes & Tonsils

• Enlarged, edematous, hemorrhagic
• Tonsils appear red and swollen

Spleen

• Enlarged (splenomegaly)
• Mottled parenchyma

Kidneys

• Cortical hemorrhages
• Pale foci (necrosis)
• Edema

Body Cavities

• Serosanguineous (bloody-straw colored) fluid in peritoneum, pleura, pericardium

CNS (Neurological cases)

• Hemorrhages in brain stem and spinal cord
• Edema of brain

---

📌 SECTION 7 — MICROSCOPIC PATHOLOGY (Histopathology)

Liver (Key Findings)

• Centrilobular to midzonal (zone 3) hepatocellular necrosis — this zone is most affected because it is furthest from oxygen supply and has highest exposure to toxins
• Intranuclear inclusion bodies — large, prominent, eosinophilic (early: basophilic/amphophilic), surrounded by a clear halo inside hepatocyte nuclei — these are the Cowdry Type A inclusions = PATHOGNOMONIC for adenoviral infection
• Inflammatory infiltrate: predominantly neutrophils early, mononuclear cells later
• Kupffer cell hyperplasia
• Bile duct proliferation in chronic cases

Vascular Endothelium

• Endothelial cell necrosis and inclusion bodies within endothelial cells throughout all organs
• This is why hemorrhages are widespread — the blood vessel linings are destroyed

Kidney

• Glomerulonephritis (immune complex deposition)
• Tubular necrosis with inclusion bodies
• Intranuclear inclusions in tubular epithelium

Eye

• Corneal endothelial cell damage and inclusion bodies
• Inflammatory cells in anterior chamber (uveitis)

Brain

• Perivascular cuffing (inflammatory cells around blood vessels)
• Endothelial inclusion bodies

---

📌 SECTION 8 — CLINICAL PATHOLOGY (Laboratory Findings)

Complete Blood Count (CBC)

Serum Biochemistry

Coagulation Profile

• Prothrombin time (PT) — prolonged
• Activated partial thromboplastin time (aPTT) — prolonged
• Fibrinogen — decreased
• FDPs (fibrin degradation products) — elevated
• D-dimers — elevated
• Diagnosis: Disseminated Intravascular Coagulation (DIC)

Urinalysis

• Proteinuria (glomerular damage)
• Hematuria (blood in urine)
• Granular casts
• Virus can be detected in urine

---

📌 SECTION 9 — DIAGNOSIS

Presumptive (Clinical) Diagnosis

• Unvaccinated dog with sudden onset fever, hepatomegaly, jaundice, hemorrhages, abdominal pain
• Marked leukopenia + elevated liver enzymes
• "Blue eye" developing during recovery
• Gallbladder edema on ultrasound

Definitive Ante-mortem (In Living Dog) Tests

Post-mortem (Necropsy) Diagnosis

• Gross: Edematous gallbladder, petechiae, hepatomegaly
• Histopath (H&E stain): Intranuclear inclusion bodies in hepatocytes + endothelium = diagnostic
• IHC: Anti-CAV-1 antibody staining confirms antigen in tissue
• PCR on tissue: Molecular confirmation

Differential Diagnosis (Diseases to Rule Out)

---

📌 SECTION 10 — TREATMENT

Critical Note: There is NO specific antiviral drug approved for CAV-1. All treatment is supportive and symptomatic.

Goals of Treatment

1. Support fluid balance and circulation
2. Maintain liver function
3. Control coagulopathy (DIC)
4. Prevent secondary bacterial infections
5. Support nutrition
6. Manage eye lesions

1. Fluid Therapy (MOST IMPORTANT)

• IV crystalloids (Lactated Ringer's Solution, Normal Saline, Hartmann's)
• Correct dehydration and electrolyte imbalances
• Add 50% Dextrose to IV fluids if hypoglycemic (hepatic failure impairs gluconeogenesis)
• Rate: Based on dehydration status + maintenance + ongoing losses

2. Colloid/Plasma Support

• Fresh Frozen Plasma (FFP): Provides coagulation factors — essential in DIC
• Whole blood transfusion: If severe anemia + hemorrhage
• Albumin infusion: If severe hypoalbuminemia causing ascites/edema
• Synthetic colloids (hetastarch) cautiously if plasma not available

3. Coagulopathy Management (DIC)

• Fresh Frozen Plasma — primary treatment for coagulopathy
• Heparin (low-dose): Controversial — may be used in early DIC to prevent further fibrin clot formation; use under specialist guidance only
• Vitamin K1: If vitamin K-dependent factor deficiency suspected (though less common in pure ICH)
• Platelet-rich plasma if severe thrombocytopenia

4. Antimicrobials (Antibiotics)

• NOT for CAV-1 itself (viral disease, antibiotics don't kill viruses)
• Given to prevent secondary bacterial infections (common when liver and immune function are compromised)
• Broad-spectrum: Ampicillin or Amoxicillin-clavulanate + Enrofloxacin (or Metronidazole for anaerobic cover)
• Avoid hepatotoxic antibiotics (e.g., tetracyclines, some aminoglycosides)

5. GI Protection

• Anti-emetics: Metoclopramide, Maropitant (Cerenia) — for vomiting
• Proton pump inhibitors/H2 blockers: Omeprazole, Famotidine — for gastric ulceration
• Sucralfate: Gastroprotection for upper GI ulcers (give separately from other drugs)
• Gut motility: Metronidazole (Flagyl) — also has some anti-anaerobic and hepatoprotective properties

6. Hepatoprotectants / Liver Support

• S-Adenosylmethionine (SAMe): Antioxidant, reduces oxidative stress on liver
• Milk Thistle (Silymarin): Hepatoprotective antioxidant
• Ursodiol (Ursodeoxycholic acid): Promotes bile flow, anti-inflammatory in liver
• N-Acetylcysteine (NAC): Replenishes glutathione, strong hepatoprotective effect

7. Nutritional Support

• Dogs with liver failure should receive high-quality, moderate protein diet (not protein-restricted unless hepatic encephalopathy)
• Offer small frequent meals
• Nasoesophageal tube feeding if anorexic
• Avoid high-fat meals (biliary involvement)

8. Ocular Treatment ("Blue Eye")

• Topical atropine (1%) — for uveitis-associated pain and miosis
• Topical corticosteroids (prednisolone acetate 1%) — if no corneal ulcer present
• Topical NSAIDs — may be used as alternative
• Artificial tears — for corneal edema
• Most cases resolve in 2–4 weeks spontaneously
• Keep in low-light environment (photophobia)

9. Antiviral Therapy

• No licensed antivirals for CAV-1 exist currently
• Experimental use of cidofovir (broad-spectrum antiviral against DNA viruses) has been discussed but not standard practice
• Interferon-alpha: Some investigational use as immunomodulator, not standard

10. Isolation & Barrier Nursing

• Isolate infected dogs immediately from other dogs
• Strict hygiene — barrier gowns, dedicated instruments
• Disinfect environment with bleach (1:30 dilution)
• Urine is infectious for 6+ months post-recovery — continued isolation of recovered dogs

---

📌 SECTION 11 — PROGNOSIS

• Chronic active hepatitis (up to months–years later)
• Chronic glomerulonephritis with proteinuria
• Persistent corneal edema (rare)
• Long-term viral shedding in urine (≥6 months)

---

📌 SECTION 12 — PREVENTION & VACCINATION

Vaccine Type — CAV-2 Modified Live Virus (MLV)

• Why CAV-2, not CAV-1?
  • Old live CAV-1 vaccines caused "post-vaccinal blue eye" (corneal edema) and renal localization in a % of dogs — so they were replaced
  • CAV-2 is antigenically related to CAV-1 → cross-protection against CAV-1
  • CAV-2 MLV vaccine is safe, does NOT cause blue eye, and produces excellent immunity against both CAV-1 and CAV-2

WSAVA 2024 Core Vaccine Schedule

CAV-2 is a CORE VACCINE — recommended for ALL dogs worldwide regardless of lifestyle.

• Booster at 1 year after puppy series
• Then every 3 years (DOI — Duration of Immunity — for CAV is at minimum 3 years, likely lifetime)
• Serological testing (vaccine antibody titers) can substitute for routine boosters to avoid over-vaccination

• 2 doses 3–4 weeks apart
• Booster 1 year later
• Then every 3 years

Passive Immunity (Maternal Antibody)

• Puppies receive maternal antibodies (MDA) via colostrum in first 24 hours
• MDA can block vaccine response — this is why multiple puppy doses are needed
• MDA wanes by 12–16 weeks typically
• The final puppy vaccine dose at ≥16 weeks ensures vaccine works after MDA declines

Vaccine Efficacy

• Seroconversion rate: >95% with proper protocol
• Duration of Immunity: At least 3 years, studies suggest may be lifelong
• Cross-protection: CAV-2 vaccine protects against both CAV-1 (hepatitis) and CAV-2 (respiratory)

---

📌 SECTION 13 — ZOONOTIC POTENTIAL

• NO — CAV-1 is NOT a zoonosis
• Humans cannot get infectious canine hepatitis
• No human health risk from infected dogs
• However, good hygiene is still important (handling infectious materials)

---

📌 SECTION 14 — NOTABLE / UNIQUE FEATURES (Exam Favorites)

1. "Blue Eye" (Hepatitis Blue Eye): Unilateral/bilateral corneal edema from immune complex deposition in the corneal endothelium — occurs in ~25% of natural cases AND rarely after old CAV-1 vaccines
2. Edematous Gallbladder: Almost pathognomonic for ICH at necropsy
3. Intranuclear inclusions in hepatocytes: Large, eosinophilic — Cowdry Type A
4. CAV-2 vaccine protects against CAV-1: Cross-immunity due to antigenic similarity
5. Urine shedding for 6 months: Recovered dogs are still infectious
6. Peyer's patches + Tonsils = First targets: Initial viral replication sites
7. Non-enveloped virus: Resistant to many disinfectants, survives long in environment
8. DIC is the main killer: In acute cases, the coagulopathy and hepatic failure cause death

---

📌 SECTION 15 — COMMONLY ASKED QUESTIONS (Pet Owners & Students)

---

Yes, but very rarely. Vaccine failure can occur if the puppy series was incomplete, if maternal antibodies blocked vaccine response, or if the dog is severely immunocompromised. Proper vaccination at ≥16 weeks provides very high (>95%) protection.

---

Not necessarily. "Blue eye" in ICH is usually accompanied by severe systemic illness (fever, jaundice, bleeding). Corneal clouding can also result from trauma, glaucoma, dry eye, cataracts, corneal ulcer, or other causes. If your unvaccinated dog is also sick with fever and liver signs — ICH must be strongly suspected. See a vet immediately.

---

No. CAV-1 is species-specific and does NOT infect humans. It is not a zoonotic disease.

---

No licensed antiviral medicine specifically kills CAV-1. Treatment is supportive (fluids, liver support, anti-bleeding drugs, antibiotics for secondary infections). The dog's own immune system must overcome the virus.

---

YES — for at least 6 months. Recovered dogs shed CAV-1 in their urine for a prolonged period. They should be isolated from unvaccinated dogs and their urine-contaminated areas should be disinfected regularly.

---

They are completely different diseases caused by completely different viruses. ICH is caused by Canine Adenovirus Type 1 (a DNA adenovirus). Human Hepatitis A is caused by Hepatovirus A (an RNA picornavirus). They share no biological relationship.

---

The earliest recommended age is 6 weeks. However, maternal antibody interference means the final puppy vaccine dose should always be given at or after 16 weeks of age to ensure effective immune response.

---

No. Natural infection provides lifelong solid immunity against CAV-1 re-infection. The dog is fully protected after recovery. However, it may shed virus in urine for 6 months.

---

Use bleach diluted 1:30 (1 part bleach to 30 parts water). CAV-1 is resistant to ether, alcohol, and many common disinfectants because it has no lipid envelope. Iodophors and quaternary ammonium compounds are also effective. Clean all surfaces, food bowls, bedding, and floors. Discard porous materials (fabric, wood).

---

Both are canine adenoviruses but they cause different diseases:

• CAV-1 → Infectious Canine Hepatitis (liver, kidneys, blood vessels)
• CAV-2 → Infectious Tracheobronchitis / Kennel Cough (upper respiratory tract) The CAV-2 vaccine is used to protect against both because they share cross-reactive antigens.

---

Yes. Wild canids (foxes, wolves, coyotes) and even bears can harbor CAV-1 and shed it in their feces and urine. Dogs that have contact with wildlife areas and are not vaccinated are at risk.

---

Key findings:

• Severe leukopenia (very low white blood cells) — especially in first 3–4 days
• Very high ALT, AST (liver enzymes)
• Elevated bilirubin (jaundice)
• Low platelets (thrombocytopenia — bleeding risk)
• Prolonged PT and aPTT (coagulation failure)
• Hypoglycemia (liver cannot make glucose)
• Proteinuria on urinalysis

---

Yes — this is the peracute form. The puppy may be found dead in the morning with no prior warning, or may collapse and die within hours of first appearing unwell. This is most common in very young, unvaccinated puppies < 3 months old.

---

Not always, but edema and thickening of the gallbladder wall is a highly characteristic and nearly pathognomonic finding that strongly suggests ICH when found at necropsy. It is one of the most important gross pathology findings for a vet student to remember.

---

In order of importance:

1. Liver — hepatomegaly, necrosis, inclusion bodies
2. Gallbladder — edematous, thickened wall
3. Lymph nodes — enlarged, hemorrhagic
4. Spleen — enlarged, mottled
5. Kidneys — cortical hemorrhages, glomerulonephritis
6. Brain — hemorrhages in neurological cases
7. Serosal surfaces — widespread petechiae/ecchymoses

---

📌 QUICK REVISION SUMMARY TABLE

---

• Merck/MSD Veterinary Manual — Infectious Canine Hepatitis (2024 edition)
• WSAVA 2024 Vaccination Guidelines for Dogs and Cats
• AAHA 2022 Canine Vaccination Guidelines
• Decaro N, Martella V, Buonavoglia C. Canine adenoviruses and herpesvirus. Vet Clin North Am Small Anim Pract. 2008 Jul [PMID: 18501279] — Peer-reviewed review
• Hornsey SJ et al. CAV-1 causing neurological signs in a 5-week-old puppy. BMC Vet Res. 2019 [PMID: 31752890]
• Wong M et al. Novel recombinant CAV-1 in acute lethal ICH. Viral Immunol. 2017 [PMID: 28426340]
• Li Y et al. CAV-1 induces PANoptosis via AIM2 inflammasome. Vet Microbiol. 2026 [PMID: 41793985] — Most recent research
• ASKJPC Veterinary Pathology Database — Gross and microscopic ICH findings

---

🐕 CANINE PARAINFLUENZA VIRUS (CPIV) — Complete Veterinary Guide

---

📌 SECTION 1 — BASIC IDENTITY & CLASSIFICATION

What is CPIV?

Virus Classification (Full Taxonomy)

Important note on naming: CPIV was first isolated from rhesus monkey and cynomolgus monkey kidney cells in 1956 and named Simian Virus 5 (SV5). Later renamed Parainfluenza Virus 5 (PIV5) and recognized as a primary canine pathogen causing tracheobronchitis.

---

📌 SECTION 2 — VIRAL STRUCTURE & PROTEINS (Molecular Biology)

Surface Proteins

• A dual-function glycoprotein on the viral envelope
• Hemagglutinin function: Binds sialic acid residues on host respiratory epithelial cell surfaces → allows virus to attach to and enter cells
• Neuraminidase function: Cleaves sialic acid on host cell surface during viral budding → allows newly formed virions to be released and spread to other cells
• The HN protein is the primary target of neutralizing antibodies (immune protection)

• Mediates fusion of the viral envelope with the host cell membrane → allows viral RNA to enter the cytoplasm
• Also promotes cell-to-cell fusion → forms syncytia (giant multinucleated cells) in infected tissue
• F protein works in coordination with HN protein

• Located in the viral envelope
• Inhibits TNF-alpha (tumor necrosis factor-alpha) signaling → prevents apoptosis (programmed death) of infected cells
• This allows infected cells to survive longer → virus replicates more → more viral spread

Internal (Non-Structural/Regulatory) Proteins

• This is one of the most studied and important CPIV proteins for understanding pathogenesis
• Antagonizes the interferon (IFN) response: V protein degrades STAT1 and STAT2 transcription factors (key interferon signaling molecules) → blocks the innate antiviral interferon pathway
• Prevents innate immune activation: Blocks MDA5 (an intracellular RNA sensor) — prevents the cell from detecting viral RNA
• Escapes adaptive immunity: Interferes with dendritic cell function and antigen presentation
• Net result: CPIV can replicate in the respiratory tract for longer before the immune system mounts an effective response

---

📌 SECTION 3 — EPIDEMIOLOGY (Who Gets It, Where, and How Often?)

Prevalence — CPIV is the MOST COMMON Viral Pathogen in CIRDC

• CPIV was detected in 9–22% of CIRDC cases per year
• CPIV was the single most prevalent viral agent in CIRDC (outranking CAV-2, CDV, CIV, CRCoV)
• Co-infection with bacteria (especially Mycoplasma canis, M. cynos, Bordetella bronchiseptica) was common

Host Range

• Primary host: Domestic dogs (Canis lupus familiaris)
• Also affects: Cats (rare, usually subclinical), humans (humans have their own parainfluenza viruses — CPIV/PIV5 has been occasionally detected in human respiratory samples but is NOT a recognized significant human pathogen)

Age Predisposition

• All ages can be infected
• Most severe disease: Puppies < 6 months (immature immune system)
• Adults with partial immunity: Milder or subclinical infection
• Older, immunocompromised, or stressed dogs: More severe disease

High-Risk Situations (Where Outbreaks Occur)

• Kennels and boarding facilities — hence "Kennel Cough"
• Animal shelters — high dog density, stress-induced immunosuppression
• Dog shows and competitions
• Dog parks
• Veterinary hospital wards (hospitalized dogs)
• Breeding facilities (puppies highly susceptible)
• Grooming salons

Geographic Distribution

• Worldwide — every country with domestic dog populations
• No seasonal predilection, but outbreaks increase in summer/fall when dogs are boarded during owner vacations

---

📌 SECTION 4 — TRANSMISSION (How Does It Spread?)

Primary Route: AIRBORNE (Aerosol)

• Infectious aerosol droplets released when infected dogs cough, sneeze, or bark
• Very efficient transmission — one coughing dog in a kennel can infect all susceptible dogs within hours

Secondary Routes

• Direct contact — nose-to-nose contact, licking, shared food/water bowls
• Fomites — contaminated hands of handlers, bedding, collars, leashes
• Virus in nasal and oropharyngeal secretions during the shedding period

Viral Shedding Period

• Infected dogs shed CPIV from the respiratory tract for up to 2 weeks post-infection
• Shedding begins during the incubation period (before clinical signs appear) — this is why it spreads so rapidly in kennels

Environmental Survival

• CPIV is an enveloped virus — the lipid envelope makes it LESS stable in the environment compared to non-enveloped viruses (like parvovirus or CAV-1)
• Relatively sensitive to disinfectants: Killed by common disinfectants including:
  • Quaternary ammonium compounds
  • Chlorhexidine
  • Bleach (sodium hypochlorite)
  • Iodophors
  • Most detergents
• Survives longer in cool, moist conditions

Incubation Period

• 3–10 days (most commonly 5–6 days)

---

📌 SECTION 5 — PATHOGENESIS (Step-by-Step Mechanism)

Step 1 — Virus Entry: Inhalation/Ingestion

• Virus is inhaled via aerosol or enters oronasally
• HN protein binds to sialic acid residues on the surface of respiratory epithelial cells lining the nasal mucosa, trachea, and bronchi

Step 2 — Membrane Fusion & Cell Entry

• The F protein mediates fusion of the viral envelope with the host cell plasma membrane
• Viral nucleocapsid (RNA + NP proteins) enters the cytoplasm
• Viral RNA is released and transcribed in the cytoplasm (paramyxoviruses replicate entirely in the cytoplasm, NOT the nucleus)

Step 3 — Viral Replication & Immune Evasion

• The RNA-dependent RNA polymerase (L+P proteins) copies the viral genome
• The V protein blocks the interferon response → the cell does not sound the alarm efficiently → virus replicates freely
• The SH protein blocks TNF-alpha → prevents apoptosis → infected cells survive longer, allowing more viral production

Step 4 — Epithelial Cell Damage

• As virus replicates within and destroys respiratory epithelial cells:
  • Ciliostasis — cilia of the respiratory epithelium stop beating (ciliary paralysis)
  • Ciliary destruction — cilia are physically damaged and lost
  • Epithelial necrosis — superficial epithelial cells die and slough off
• The mucociliary escalator (the normal defense system that traps and removes particles/bacteria from the airway) is severely impaired

Step 5 — Mucosal Inflammation

• Neutrophils infiltrate the damaged epithelium → acute inflammatory response
• Mucus secretion increases → productive or non-productive cough
• Affected sites: nasal mucosa, pharynx, larynx, trachea, bronchi, bronchioles

Step 6 — Secondary Bacterial Colonization (KEY Complication)

• The damaged, denuded epithelium is now susceptible to bacterial invasion
• Normal upper respiratory bacteria (which were previously held in check by intact mucosa + mucociliary clearance) now invade deeper:
  • Bordetella bronchiseptica — most important co-infecting bacterium
  • Mycoplasma canis, Mycoplasma cynos
  • Streptococcus equi subsp. zooepidemicus
  • Pasteurella spp.
  • Gram-negative rods
• This bacterial secondary infection is what converts mild viral tracheobronchitis into severe bronchopneumonia

Step 7 — Resolution or Progression to Pneumonia

• Uncomplicated CPIV alone:
  • Self-limiting in 1–2 weeks in immunocompetent adult dogs
  • Mucosal regeneration occurs after viral clearance
• With co-infections or in immunocompromised/young dogs:
  • Disease extends to the lower airways and alveoli
  • Bronchopneumonia develops — potentially fatal in puppies
  • Interstitial pneumonia pattern

---

📌 SECTION 6 — CANINE INFECTIOUS RESPIRATORY DISEASE COMPLEX (CIRDC)

What is CIRDC?

Pathogens in CIRDC

Why Co-infection Matters

• CPIV + Bordetella bronchiseptica = synergistic pathogenicity — together they cause far more severe disease than either alone
• CPIV destroys the mucociliary defense → Bordetella exploits the damaged mucosa to colonize deeply
• Multiple co-infections → more severe, longer, and harder-to-treat disease

---

📌 SECTION 7 — CLINICAL SIGNS

Uncomplicated CPIV Infection (Mild Form)

• Sudden onset dry, harsh, "honking" cough — the hallmark sign
  • Cough is often paroxysmal (comes in bouts/fits)
  • Provoked or worsened by excitement, exercise, pressure on trachea (collar), and tracheal palpation
  • Dogs may gag or retch at the end of a coughing fit (sometimes mistaken by owners as vomiting)
• Mild fever (39.5–40°C / 103–104°F) or normal temperature
• Serous to mucopurulent nasal discharge (clear initially, may become cloudy/yellow with secondary bacterial infection)
• Serous ocular discharge (mild conjunctivitis)
• Mild pharyngitis — mild redness of the throat
• Tonsillitis — tonsils may be enlarged
• Appetite usually normal or slightly decreased
• Fatigue — mild; dog is usually still alert and reasonably active

Complicated / Severe CPIV Infection

• Progression of cough from dry/harsh to moist/productive cough (indicates lower airway involvement)
• High fever (40–41°C / 104–106°F)
• Marked lethargy, depression, profound anorexia
• Thick, mucopurulent nasal discharge (yellow-green)
• Dyspnea (difficulty breathing) — increased respiratory rate, labored breathing
• Cyanosis (blue-tinged mucous membranes) — in severe pneumonia
• Crackles and wheezes on pulmonary auscultation
• Weight loss
• Can be fatal in young puppies

Subclinical Form

• Some dogs, especially partially immune adults, show no signs but shed virus
• They act as silent carriers and spread infection

---

📌 SECTION 8 — GROSS PATHOLOGY (Necropsy Findings)

Upper Respiratory Tract

• Nasal mucosa: Congestion, hyperemia, mucopurulent exudate
• Trachea and bronchi: Hyperemic (reddened) mucosa; excessive mucus or mucopurulent exudate in the lumen; tracheal epithelium may appear roughened due to epithelial loss

Lymph Nodes

• Mandibular and retropharyngeal lymph nodes: Enlarged, edematous — draining the upper respiratory tract
• Bronchial and mediastinal lymph nodes: Enlarged with reactive lymphadenopathy

Lungs (in complicated bronchopneumonia cases)

• Cranioventral consolidation — the cranioventral (front-bottom) lobes are most commonly affected (gravity-dependent area)
• Affected lung lobes: Firm, dark red to grey-pink, airless
• Hepatization — lung lobes have a liver-like consistency (due to exudate-filled alveoli)
• Mucopurulent exudate can be expressed from cut bronchi
• Pleural surface may show fibrin deposits (pleuritis) in severe cases
• Lung emphysema (air trapping) in other areas

Tonsils

• Enlarged, congested, occasionally ulcerated

---

📌 SECTION 9 — MICROSCOPIC PATHOLOGY (Histopathology)

Trachea and Bronchi

• Loss of cilia from respiratory epithelium — ciliostasis progresses to ciliary destruction
• Epithelial degeneration and necrosis — superficial epithelial cells degenerate, detach, slough into the lumen
• Increased goblet cell activity — excessive mucus production
• Submucosal edema — fluid accumulation beneath the epithelium
• Inflammatory infiltrate: Neutrophils and lymphocytes in the submucosa

Lung (in Bronchopneumonia)

• Neutrophilic exudate filling alveoli (suppurative pneumonia)
• Fibrin in alveolar spaces
• Type II pneumocyte hyperplasia (reparative response)
• Peribronchiolar lymphocytic infiltration
• In severe/viral interstitial pneumonia: Diffuse alveolar damage, thickened alveolar walls

Important Note on Inclusions

• CPIV does NOT produce intranuclear inclusion bodies (unlike CAV-1 which has classic Cowdry Type A intranuclear inclusions)
• CPIV replicates in the cytoplasm — small cytoplasmic inclusions may occasionally be seen but are NOT a consistent or pathognomonic finding
• This is a key differentiator from adenoviral infections

---

📌 SECTION 10 — CLINICAL PATHOLOGY (Laboratory Findings)

CBC (Complete Blood Count)

Serum Biochemistry

• Usually normal in uncomplicated CPIV (unlike ICH where liver enzymes are markedly elevated)
• May show mild elevation in inflammatory markers (fibrinogen, acute phase proteins)
• In severe pneumonia: Hypoxemia-related changes

Arterial Blood Gas (ABG)

• In severe pneumonia/respiratory compromise:
  • Decreased PaO2 (hypoxemia)
  • Increased PaCO2 (hypercapnia) in late/severe disease
  • Respiratory acidosis (pH decreases)

Urinalysis

• Usually normal

---

📌 SECTION 11 — DIAGNOSIS

Clinical Diagnosis (Presumptive)

• History of exposure (kenneling, dog show, boarding)
• Classic dry, harsh "goose-honk" cough in an otherwise alert dog
• Tracheal sensitivity on palpation (touch the trachea gently → triggers paroxysmal coughing — a simple, reliable in-clinic test)
• Serous nasal discharge
• Mild or no fever
• Often normal CBC and blood chemistry

Definitive Laboratory Diagnosis

Imaging

• Thoracic Radiographs (X-rays):
  • Uncomplicated CPIV: Normal or mild peribronchial pattern ("bronchial pattern" — thickening of bronchial walls visible as "doughnuts" or "tramlines")
  • With bronchopneumonia: Cranioventral alveolar pattern (fluffy white infiltrate in cranioventral lung lobes)
  • Interstitial pattern in viral pneumonia

Bronchoscopy / BAL (Bronchoalveolar Lavage)

• Used in refractory or complicated cases
• Allows direct visualization of airways
• BAL fluid cytology: Neutrophils (suppurative inflammation), bacteria
• BAL fluid culture and sensitivity: Identifies secondary bacterial pathogens
• BAL fluid PCR: Identifies viral and bacterial etiologies

Differential Diagnosis (What Else Could It Be?)

---

📌 SECTION 12 — TREATMENT

For Uncomplicated CPIV Kennel Cough (Mild Cases)

• Strict rest — no exercise, no excitement (excitement triggers coughing fits)
• Remove collar if it presses on trachea — use a harness instead
• Keep dog away from other dogs (isolation — prevent spread)

• Used when cough is severe, non-productive, and distressing the dog or disrupting sleep
• Butorphanol tartrate (0.05–0.1 mg/kg PO q6–12h) — opioid antitussive; most effective
• Hydrocodone — opioid antitussive; effective but controlled substance
• Codeine — mild opioid cough suppressant
• Dextromethorphan — mild, OTC; less effective but safe
• Important: Do NOT suppress cough in productive pneumonia — coughing helps clear secretions from the airway

• Used when bronchospasm is present (wheeze on auscultation)
• Aminophylline/Theophylline — methylxanthine bronchodilator
• Terbutaline — beta-2 agonist bronchodilator
• Albuterol (Salbutamol) — nebulized for direct airway delivery

• Steam humidifier or nebulized saline helps loosen and mobilize secretions
• Nebulized with mucolytics (N-acetylcysteine) in thick secretion cases
• Nebulized antibiotics in complicated cases

• NSAIDs (Meloxicam, Carprofen): For fever and airway inflammation, if no contraindications
• Corticosteroids (Prednisolone): Used at low anti-inflammatory doses in severe airway edema/bronchospasm — use cautiously as they can suppress immune response and worsen secondary infections; short course only

For Complicated CPIV (Bacterial Pneumonia/Secondary Infections)

• BAL fluid culture and sensitivity testing (C&S)
• Gram stain of BAL fluid
• Clinical presentation

Additional Supportive Care in Severe Cases

• IV crystalloids (LRS or 0.9% NaCl) for dehydrated, anorexic, or severely ill dogs
• Correct electrolyte imbalances

• Nasal cannula, oxygen cage, or mask — for hypoxemic dogs (SpO2 < 92% on room air)
• Flow-by oxygen initially (less stressful)
• Oxygen cage: 40–50% O2 concentration

• Encourage eating — offer warmed, palatable food
• Nasoesophageal tube feeding if anorexic for >48–72 hours

• No licensed antivirals against CPIV in dogs
• Interferons (recombinant feline interferon omega — Virbagen) have been used experimentally; not standard
• Supportive care is the mainstay

• Strict isolation from other dogs for the full shedding period (minimum 2 weeks from onset of signs)
• Handler hygiene — wash hands, change clothes after handling infected dog

---

📌 SECTION 13 — PROGNOSIS

• Chronic bronchitis
• Bronchiectasis (permanent irreversible dilation of bronchi) — rare, in severe/prolonged cases
• Fibrotic lung changes

---

📌 SECTION 14 — PREVENTION & VACCINATION

WSAVA 2024 Vaccine Classification: NON-CORE

CPIV vaccine is classified as NON-CORE by WSAVA — meaning it is recommended based on risk of exposure, NOT universally for all dogs.

• Dogs that are regularly boarded, groomed, visit dog parks, attend dog shows
• Dogs in shelters or breeding facilities
• High-density living situations

Vaccine Types Available

• Combined with other core vaccines (distemper, parvovirus, CAV-2) in DHPPi or DA2PPi combination vaccines
• Administered by subcutaneous injection
• Produces systemic (serum) IgG antibodies
• Limitations: Does not produce strong local mucosal IgA immunity at the respiratory mucosa — where protection is most needed
• Takes 3–5 days after the final dose to develop protective immunity

• Combined with Bordetella bronchiseptica (± CAV-2) — e.g., Nobivac Intra-Trac KC, Bronchi-Shield
• Administered directly into one or both nostrils
• Produces mucosal IgA at the respiratory tract — more relevant local protection
• Also stimulates systemic immunity
• Faster onset of immunity: 3–5 days (vs. 3–5 days for injectable — but intranasal provides better local mucosal protection)
• Can cause mild, transient serous nasal discharge for a few days post-vaccination (mild vaccine reaction)
• Important advantage: Intranasal vaccines are NOT affected by maternal antibody interference (unlike injectable vaccines) — useful in young puppies
• Preferred route when high-risk exposure (e.g., pre-boarding within 3–5 days)

WSAVA 2024 Vaccination Schedule for CPIV

• 2 doses 2–4 weeks apart

• CPIV parenteral: Annually (duration of immunity shorter than core vaccines)
• CPIV intranasal: Annually (or before periods of high exposure, e.g., before boarding)

• Give intranasal CPIV + Bordetella vaccine at least 3–5 days before boarding to allow immunity to develop

AAHA 2022 Guidelines on CPIV

• CPIV vaccine classified as "lifestyle/non-core"
• Recommended for dogs with risk of exposure to other dogs
• Combined DHPPi vaccines are commonly used and include CPIV as standard in many protocols

Note on Combined Vaccines

• D = Canine Distemper Virus (CDV)
• A2/H = CAV-2 (protects against CAV-1 and CAV-2)
• P/Parvo = Canine Parvovirus
• Pi = Parainfluenza (CPIV) So in practice, most dogs receiving routine core vaccination are also getting CPIV vaccination without the owner even knowing it separately.

---

📌 SECTION 15 — ZOONOTIC POTENTIAL

• CPIV (PIV-5) has been occasionally isolated from humans, particularly from healthcare workers and laboratory workers with close contact with primates or dogs
• However, CPIV is NOT a recognized zoonotic public health threat
• Healthy humans are not at significant risk
• Immunocompromised humans (HIV/AIDS, cancer patients, transplant recipients) should exercise caution — basic hygiene is recommended
• Humans have their own distinct parainfluenza viruses (hPIV 1, 2, 3, 4) which cause croup and upper respiratory infections in children — these are genetically different from CPIV

---

📌 SECTION 16 — UNIQUE / NOTABLE FEATURES (Exam Favorites)

1. CPIV = Most prevalent viral pathogen in CIRDC — outranking CAV-2, CDV, and CIV (Yondo et al., 2023)
2. V protein = Interferon antagonist — key virulence factor for immune evasion; blocks innate antiviral response
3. SH protein blocks TNF-alpha → prevents infected cell apoptosis → virus replicates longer
4. Enveloped virus → sensitive to common disinfectants (unlike parvovirus or adenovirus)
5. Replicates in cytoplasm — NO intranuclear inclusion bodies (differentiates from adenovirus)
6. Intranasal vaccine preferred over injectable for rapid onset mucosal immunity before high-risk events
7. Non-core vaccine — only recommended based on lifestyle/risk (WSAVA 2024)
8. Shedding for up to 2 weeks — even before clinical signs appear (presymptomatic shedding)
9. CPIV alone = mild, self-limiting — the severe disease comes from co-infection with Bordetella and Mycoplasma
10. Tracheal palpation test — pressing on the trachea in the clinic triggers a coughing fit in affected dogs — simple, useful diagnostic maneuver

---

📌 QUICK REVISION SUMMARY TABLE

---

📌 COMMONLY ASKED QUESTIONS (Q&A Section)

---

No. "Kennel Cough" (officially called Canine Infectious Respiratory Disease Complex, CIRDC, or Infectious Tracheobronchitis) is a syndrome with many possible causes. CPIV is the most common viral cause, but Bordetella bronchiseptica, CAV-2, Mycoplasma, and other pathogens are also involved. Most cases involve multiple pathogens at once.

---

Yes, absolutely. The CPIV vaccine is classified as non-core, so not all dogs receive it. Even vaccinated dogs can get CIRDC because:

• The vaccine may not fully protect against all strains
• Other pathogens (Bordetella, Mycoplasma, CIV) not covered by the vaccine may be the cause
• Vaccine immunity can wane Vaccination reduces severity and duration but does not give 100% protection.

---

Key differences:

• Kennel cough (CPIV): Alert, eating reasonably well, dry harsh cough, no neurological signs, no skin hardening, no eye discharge (or mild serous discharge), temperature normal or mildly elevated
• Distemper (CDV): Very ill, not eating, high fever, neurological signs (seizures, twitching), thick mucopurulent eye and nose discharge, hard-pad disease (hyperkeratosis of paw pads), more severe progression If in doubt — take your dog to a vet. PCR testing can definitively distinguish.

---

Persistent cough beyond 2–3 weeks suggests:

• Secondary bacterial infection that needs longer antibiotic treatment (4+ weeks minimum)
• Co-infection with other pathogens not covered by current antibiotic
• Development of bronchopneumonia — needs chest X-ray
• Tracheal collapse (non-infectious) unmasked by respiratory inflammation
• Chronic bronchitis Your vet should do a thoracic radiograph, and possibly BAL with culture and sensitivity testing.

---

You should wait at least 2 full weeks from resolution of all clinical signs before boarding. The dog should be fully recovered and not shedding virus. Inform the kennel of the recent illness. Ensure the dog has received the intranasal CPIV + Bordetella vaccine (at least 3–5 days before boarding for the intranasal vaccine to take effect).

---

Both work, but they have different advantages:

• Intranasal: Faster onset (3–5 days), produces local mucosal IgA (where the virus actually enters), can be used in young puppies despite maternal antibodies, better for pre-boarding preparation
• Injectable: Part of routine combination vaccine (DHPPi), systemic immunity, easier to administer without struggle For dogs at routine risk: injectable DHPPi is convenient. For dogs about to be boarded or in high-risk situations: intranasal vaccine is preferred.

---

No. CPIV is not a recognized human pathogen and does not cause disease in healthy humans. Bordetella bronchiseptica (the bacterium often co-infecting with CPIV) is occasionally reported in immunocompromised humans (HIV, cancer, transplant patients) — such patients should be cautious and practice good hygiene around infected dogs.

---

Great question. Antibiotics do NOT kill viruses. They are given to:

1. Treat secondary bacterial infections (Bordetella, Mycoplasma, etc.) that take advantage of the virus-damaged respiratory mucosa
2. Prevent bacterial pneumonia from developing in at-risk dogs In uncomplicated mild CPIV kennel cough in a healthy adult dog, antibiotics are often NOT necessary and should be withheld to reduce antibiotic resistance.

---

Currently, no antiviral drug is licensed specifically for CPIV in dogs. The virus is self-limiting in most cases, which is why pharmaceutical development of a specific antiviral has not been a high priority. Experimental use of interferons has been explored. For now, supportive care and vaccination remain the cornerstones of management.

---

Because CPIV is an enveloped virus, it is much easier to kill than non-enveloped viruses. Use any of:

• Bleach (sodium hypochlorite) 1:32 dilution
• Quaternary ammonium compounds
• Chlorhexidine
• Iodophors (povidone-iodine) Clean all surfaces, food bowls, bedding, kennel runs. Allow to air dry. CPIV does not survive long on surfaces once disinfected.

---

Puppies at risk of kennel cough (those going to puppy classes, dog parks, boarding) should receive it:

• Intranasal CPIV vaccine can be given as early as 3–4 weeks of age in high-risk shelter situations
• Routine: as part of DHPPi from 6–8 weeks
• Pre-boarding: Intranasal vaccine at least 3–5 days before exposure
• Maternal antibody interference is less of a problem with intranasal vaccines

---

Yes, but it is uncommon. CPIV alone typically causes self-limiting tracheobronchitis. Severe viral interstitial pneumonia from CPIV alone can occur in puppies or severely immunocompromised dogs. However, in most clinical cases, bacterial co-infection (especially Bordetella and Mycoplasma) is the main driver of pneumonia, not CPIV alone.

---

These are completely different viruses:

Feature	CPIV	CIV
Virus family	Paramyxoviridae	Orthomyxoviridae
Genome	ssRNA− non-segmented	ssRNA− segmented (8 segments)
Subtypes	Only 1 type	H3N8, H3N2 subtypes
Disease	Kennel cough (mild-moderate)	Influenza (more severe, systemic)
Mortality	Very low	Higher, especially H3N2
Vaccine	Non-core	Non-core

---

Isolate the dog from other dogs for at least 2 weeks from the onset of clinical signs (or 2 weeks from the last day of clinical signs if mild). Since shedding can begin before signs appear and continue for up to 2 weeks, assume the dog is contagious throughout this period.

---

The V protein is CPIV's primary immune evasion weapon:

• It blocks interferon (IFN) synthesis and signaling (the cell's main antiviral alarm system)
• It degrades STAT1 and STAT2 proteins (key signal molecules for interferon response)
• It prevents dendritic cells from activating T cells properly This means the dog's innate immune system is "blinded" for longer, allowing the virus to replicate more before being cleared. This is why CPIV can spread so efficiently in kennels — dogs may not mount a rapid immune response. Research into blocking the V protein is ongoing as a potential therapeutic or vaccine target.

---

• Merck/MSD Veterinary Manual — Kennel Cough section (2024)
• WSAVA 2024 Guidelines for Vaccination of Dogs and Cats
• AAHA 2022 Canine Vaccination Guidelines
• Buonavoglia C & Martella V. Canine respiratory viruses. Vet Res. 2007 [PMID: 17296161]
• Reagan KL & Sykes JE. Canine Infectious Respiratory Disease. Vet Clin North Am Small Anim Pract. 2020 [PMID: 31813556]
• Yondo A et al. Predominance of CPIV and Mycoplasma in CIRDC. Pathogens. 2023 [PMID: 38003820]
• Cheng H et al. Molecular biology of CPIV V protein. Front Microbiol. 2023 [PMID: 38173672]
• The Native Antigen Company — CPIV Background Review

---

🐕 CORONAVIRUS IN DOGS — Complete Veterinary Guide

---

📌 SECTION 1 — OVERVIEW: HOW MANY CORONAVIRUSES AFFECT DOGS?

Key Point for Vet Students: When owners or examiners say "coronavirus in dogs" they almost always mean CCoV (enteric form). But a good vet knows BOTH coronaviruses exist and cause very different diseases.

---

📌 SECTION 2 — PART A: CANINE ENTERIC CORONAVIRUS (CCoV)

---

2.1 Classification & Virology

---

2.2 Viral Types and Genotypes — CRITICALLY IMPORTANT

• Found only in dogs
• More closely related to Feline Coronavirus Type I (FCoV-I)
• Grows poorly in cell culture (difficult to isolate in laboratory)
• Generally causes mild or subclinical enteric infection
• Contains an additional open reading frame (ORF3) not present in Type II

• Believed to have arisen from recombination between CCoV-I-like and TGEV-like (porcine) coronaviruses
• Grows well in cell culture
• Two subtypes:
  • CCoV-IIa: Classic canine strain; associated with both mild enteric disease AND the emerging pantropic (systemic fatal) form
  • CCoV-IIb: Result of recombination with Transmissible Gastroenteritis Virus (TGEV) of pigs — contains TGEV spike protein sequences

Pantropic CCoV-IIa — The Dangerous Emerging Variant ⭐

• First officially described by Buonavoglia et al. (2006), Italy
• Fatal multisystemic outbreaks documented in France, Belgium, Italy, Hungary, Greece, Netherlands, Australia, and elsewhere
• Has acquired the ability to spread BEYOND the intestine into all organs (pantropic = affecting all tissues)
• This is considered an emerging infectious disease of global importance

---

2.3 Viral Structure & Key Proteins

• Large glycoprotein forming the crown-like projections on the viral surface
• Mediates attachment to host cell receptor (mainly aminopeptidase N — APN on enterocytes)
• Mediates fusion of viral envelope with host cell membrane
• Primary target of neutralizing antibodies — most important for immune protection
• Highly variable between strains — key factor in determining host range, tropism, and virulence
• Recombination in the spike gene is the main reason new CCoV variants emerge with altered tropism

• Most abundant structural protein
• Spans the lipid envelope
• Plays a role in viral assembly and budding
• Interacts with nucleocapsid

• Small protein; involved in viral assembly and budding
• Plays a role in pathogenicity — ion channel activity

• Encapsulates and protects the viral RNA genome
• Involved in RNA replication

• The enormous polyprotein encoded by ORF1a and ORF1b
• Includes RNA-dependent RNA polymerase (RdRp/nsp12), helicase (nsp13), endoribonuclease (nsp15), and 3C-like protease (3CLpro/nsp5)
• 3CLpro (3C-like protease = main protease): Processes the polyprotein; key drug target in coronavirus research
• nsp16 (2'-O-methyltransferase): Caps the viral RNA to mimic host mRNA — helps evade innate immune detection

• Non-structural; roles in immune evasion, apoptosis regulation, virulence

---

2.4 Epidemiology

• CCoV is found worldwide — in every country with domestic dog populations
• Seroprevalence studies show high rates of exposure:
  • 30–60% of domestic dogs in many countries have antibodies to CCoV
  • A systematic review of Chinese dogs (Dong et al., 2022) found high prevalence across provinces
  • First isolated in 1971 in Germany from military dogs with gastroenteritis

• Puppies under 6 weeks are most severely affected
• Adults are often subclinically infected (protective immunity from prior exposure)
• Neonates (< 2 weeks) — minimal passive immunity → highest mortality risk

• Kennels, shelters, breeding facilities
• Multi-dog households
• Dog shows, puppy mills

• Can occur year-round; no strict seasonality
• Some reports of higher prevalence in colder months (increased indoor housing)

• Fecal-oral route — primary and most important
• Ingestion of feces, contaminated food, water, environment
• Direct contact with infected dog
• Fomites — contaminated objects, bedding, food bowls, shoes, hands
• Virus shed in feces beginning within 1–2 days of infection, continuing for 6–9 days in typical infection (longer in some cases)

• CCoV is enveloped → moderate stability in environment
• Inactivated by most common disinfectants (bleach, chlorhexidine, quaternary ammonium, iodophors)
• Can survive in cool, damp environments for days to weeks
• Does NOT survive well in heat, UV light, or dry conditions

• 1–4 days (very short compared to many pathogens)

---

2.5 Pathogenesis of Classic (Enteric) CCoV

Step 1 — Ingestion and Arrival in Small Intestine

• Virus is ingested orally (fecal-oral route)
• Passes through stomach (resistant to acidic pH to some extent)
• Reaches the small intestine — the primary target organ

Step 2 — Attachment to Villous Epithelial Cells

• The spike (S) protein binds to Aminopeptidase N (APN) — the receptor expressed on the apical surface of mature villous enterocytes (absorptive cells on the tips of intestinal villi)
• APN is also the receptor for Feline Coronavirus — explaining the close biological relationship

Step 3 — Viral Entry and Replication

• After S-protein/APN binding, the viral envelope fuses with the enterocyte membrane
• Viral RNA (+ssRNA) is released directly into the cytoplasm
• The RNA is immediately translated by host ribosomes into the viral polyprotein
• Viral replication occurs in the cytoplasm — replication complexes form on intracellular membranes
• New virions assembled and released by budding from the endoplasmic reticulum-Golgi intermediate compartment (ERGIC)

Step 4 — Villous Epithelial Damage

• Infected villous epithelial cells undergo degeneration and necrosis
• Cells slough from the villous tips → villous atrophy (shortening and blunting of villi)
• Critical difference from Parvovirus: CCoV infects villous tip cells (mature enterocytes) but typically SPARES the crypt epithelium — this is why CCoV is less severe than parvovirus
  • Parvovirus destroys crypt cells → destroys the stem cell population → cannot regenerate epithelium → very severe disease
  • CCoV spares crypts → crypt cells can still divide and replace the damaged villous epithelium → faster recovery

Step 5 — Malabsorptive Diarrhea

• Loss of mature absorptive enterocytes → loss of brush border enzymes (disaccharidases, peptidases) → maldigestion
• Villous atrophy → reduced absorptive surface area → malabsorption
• Osmotic diarrhea — unabsorbed nutrients draw water into the lumen
• Some secretory component — damaged enterocytes may secrete water/electrolytes
• Result: Watery, often foul-smelling, yellow-orange diarrhea ± mucus ± blood

Step 6 — Resolution (Classic CCoV)

• In healthy adult dogs and older puppies: Immune response clears the virus
• Villous epithelium regenerates from the protected crypt cells
• Diarrhea resolves in 5–7 days
• Dog recovers fully with no lasting damage (in uncomplicated cases)

---

2.6 Pathogenesis of PANTROPIC CCoV (Systemic Fatal Form)

What makes pantropic CCoV different?

• Mutations in the spike protein — particularly in the S1/S2 cleavage site and receptor-binding domain — allow the virus to:
  • Infect cells beyond the intestine (different receptor usage or altered tropism)
  • Escape immune containment in the gut
  • Spread through the bloodstream to all organs

Pantropic Pathogenesis Steps:

1. Virus enters via fecal-oral route and infects intestinal enterocytes
2. Instead of staying in the gut, virus crosses the intestinal epithelial barrier into the lamina propria
3. Viremia — virus enters the bloodstream (carried in white blood cells and free in plasma)
4. Virus infects cells in multiple organs simultaneously:
   • Leukocytes (lymphocytes, monocytes) — causes lymphopenia
   • Liver — hepatocellular necrosis
   • Spleen — splenic necrosis and lymphocyte depletion
   • Kidneys — renal tubular necrosis
   • Lungs — interstitial pneumonia
   • Brain/CNS — encephalitis, neuronal degeneration
5. Massive systemic inflammation, multiorgan failure → death

Clinical resemblance to Parvovirus: Pantropic CCoV infection can look IDENTICAL to parvovirus on clinical examination — fever, hemorrhagic gastroenteritis, profound depression, lymphopenia. This is why diagnosis requires PCR testing.

---

2.7 Co-Infection with Parvovirus (Synergism)

• CCoV + CPV-2 co-infection = dramatically more severe disease and higher mortality than either alone
• Mechanism: CCoV destroys villous enterocytes AND disrupts the mucosal barrier → parvovirus gains easier access to crypt cells AND the weakened immune system cannot fight both pathogens
• The combination causes:
  • More severe hemorrhagic gastroenteritis
  • More profound leukopenia
  • Higher death rates in puppies
  • Longer duration of illness
• Similarly, co-infection with Canine Distemper Virus (CDV) worsens CCoV disease

Clinical Pearl: Any puppy with parvovirus-like disease should ALSO be tested for CCoV, especially if not responding to standard CPV treatment.

---

2.8 Clinical Signs of Enteric CCoV

Subclinical / Inapparent Form (Most Common in Adults)

• No visible signs
• Dog seroconverts silently
• Sheds virus in feces → source of infection for other dogs

Mild / Classic Form (Typical in Puppies)

• Sudden onset diarrhea — most prominent sign
  • Watery to semi-liquid
  • Yellow-orange to green-grey color — characteristic
  • Foul-smelling, sometimes with mucus
  • Occasionally contains small amounts of blood (mild hemorrhagic component)
• Vomiting — less common and less prominent than in parvoviral enteritis
• Lethargy — mild to moderate
• Anorexia — mild, temporary
• Mild fever or normal temperature
• Dehydration — mild to moderate if diarrhea is prolonged
• Duration: 5–7 days, self-limiting

Severe / Hemorrhagic Form (Puppies < 6 weeks, Heavy Viral Load, Co-infection)

• Profuse, watery to hemorrhagic diarrhea — may be frankly bloody
• Repeated vomiting
• High fever (40–41°C / 104–106°F)
• Severe lethargy, collapse, profound depression
• Severe dehydration — sunken eyes, dry mucous membranes, skin tent test positive
• Abdominal pain on palpation

Pantropic CCoV Form (Fatal Multisystemic — Rare but Emerging)

• Hemorrhagic gastroenteritis (similar to parvovirus)
• High fever
• Neurological signs: Ataxia, seizures, altered consciousness
• Profound lymphopenia
• Rapid deterioration and death — often within 24–72 hours of signs
• Occurs mostly in puppies 4–12 weeks old
• Has been reported in adult dogs rarely

---

2.9 Gross Pathology (Necropsy Findings — CCoV)

Classic Enteric CCoV:

• Small intestine — most affected organ
  • Intestinal wall thin, flaccid, may appear pale or slightly reddened
  • Intestinal contents: Watery, yellow-orange, foul-smelling fluid; may contain gas
  • Intestinal lining appears smooth (loss of normal villous texture visible on careful inspection)
  • No crypt necrosis — this distinguishes it from parvoviral enteritis where crypts are destroyed
• Mesenteric lymph nodes: Mild enlargement, edema
• Peyer's patches: May show mild reaction
• Other organs generally normal in uncomplicated enteric form

Pantropic CCoV:

• Intestines: Hemorrhagic enteritis — mucosa severely hemorrhagic, necrotic
• Liver: Hepatomegaly, pale mottled areas, necrotic foci; occasionally petechiae on surface
• Spleen: Enlarged, congested, necrotic foci; pale areas of lymphocyte depletion
• Kidneys: Pale cortex with petechiae, necrotic foci
• Lungs: Interstitial pneumonia — lungs fail to collapse, wet/heavy, multifocal consolidation
• Brain: Hemorrhages, softening (malacia), edema
• Lymph nodes: Enlarged throughout, pale (lymphocyte depletion)
• General: Widespread petechiae/ecchymoses on serosal surfaces

---

2.10 Microscopic Pathology (Histopathology — CCoV)

Classic Enteric CCoV:

• Villous atrophy — villi are shortened, blunted, fused; villous tip cells necrotic and sloughing
• Crypt hyperplasia — crypts elongate as they try to regenerate lost villous cells (reactive)
• Lamina propria: Mild to moderate infiltration with lymphocytes, plasma cells, macrophages
• Villous epithelial cells: Vacuolation, degeneration, necrosis — most severe at villous tips
• Crypts are INTACT — this is the KEY histopathological distinguishing feature from CPV-2

Pantropic CCoV:

• Liver: Multifocal to massive hepatocellular necrosis (pericentrilobular), inflammatory infiltrate
• Spleen: Lymphocyte depletion in white pulp; necrotic foci
• Kidneys: Tubular epithelial degeneration and necrosis; interstitial nephritis
• Lungs: Interstitial pneumonia — thickened alveolar walls, type II pneumocyte hyperplasia, macrophage infiltration
• Brain: Perivascular lymphocytic infiltration; neuronal necrosis; glial nodules; demyelination
• Intestine: Crypt necrosis (in severe pantropic cases — mimicking parvovirus histologically)

---

2.11 Clinical Pathology (Lab Findings — CCoV)

Classic Enteric CCoV:

Pantropic CCoV:

---

2.12 Diagnosis of CCoV

Presumptive Diagnosis

• Young unvaccinated puppy + sudden watery/bloody diarrhea + history of exposure to other dogs or kennels
• Normal or mild leukopenia (CCoV alone does NOT cause profound leukopenia — unlike parvovirus which causes severe leukopenia)

Definitive Diagnosis

---

📌 SECTION 3 — PART B: CANINE RESPIRATORY CORONAVIRUS (CRCoV)

---

3.1 Classification & Background

• CRCoV likely originated from Bovine Coronavirus (BCoV) through a cross-species transmission event
• This is very different from CCoV (alphacoronavirus related to cat/pig viruses)
• CRCoV, BCoV, and human OC43 are so closely related genetically that CRCoV has been proposed as a naturally occurring animal model for human coronavirus respiratory infections

---

3.2 Epidemiology of CRCoV

• Worldwide distribution — found in UK, USA, Canada, Europe, Asia, Australia
• High prevalence in shelters and kennels — seropositivity rates of 40–80% in shelter dogs in some studies
• CRCoV accounts for 4–13% of CIRDC cases in diagnostic laboratory studies (Yondo et al., 2023)
• Can occur year-round; slightly more common in winter (similar to human respiratory coronaviruses)
• All ages affected; shelter dogs at highest risk due to crowding and stress
• Transmission: Airborne droplets and direct contact (respiratory route — different from CCoV which is fecal-oral)

---

3.3 Pathogenesis of CRCoV

1. Inhaled aerosol droplets deposit virus in the upper respiratory tract
2. CRCoV spike protein binds to 9-O-acetylated sialic acid receptors on the surface of nasal epithelial cells and tracheal epithelial cells
3. Virus replicates in nasal epithelium, nasal tonsil, and tracheal mucosa
4. Causes ciliary damage and epithelial necrosis in the upper airway — similar to CPIV but typically milder
5. Results in increased mucus production, nasal discharge, cough
6. CRCoV is generally NOT detected in lung parenchyma — it stays in the upper airways (unlike CPIV which can progress to lower airways)
7. Combined with other CIRDC pathogens (especially Bordetella, CPIV), produces more severe disease

---

3.4 Clinical Signs of CRCoV

• Persistent cough — dry, mild to moderate
• Nasal discharge — serous (clear), occasionally mucopurulent
• Sneezing
• Mild lethargy, reduced appetite
• No or minimal fever
• Usually self-limiting in 1–2 weeks without treatment
• Subclinical infection is common — many seropositive dogs show no signs
• Clinically indistinguishable from CPIV without diagnostic testing

---

📌 SECTION 4 — COMPARISON OF ALL CANINE CORONAVIRUSES

---

📌 SECTION 5 — TREATMENT OF CANINE CORONAVIRUS

Treatment for Classic Enteric CCoV (Mild Cases)

• Withhold food for 12–24 hours (fasting) to rest the GI tract
• Then gradual reintroduction of bland, easily digestible food:
  • Boiled chicken + boiled plain white rice (50:50)
  • Commercial GI prescription diet (Hill's i/d, Royal Canin GI)
• Small frequent meals (3–4 times daily instead of 1–2)
• Return to normal diet gradually over 5–7 days

• Oral rehydration solution (ORS) — for mild dehydration (dogs that can drink)
  • Electrolyte-glucose solution encourages water absorption
• Subcutaneous fluids — for moderate dehydration in clinic
• IV crystalloid fluids (LRS, 0.9% NaCl, Hartmann's) — for severe dehydration, vomiting, or inability to take oral fluids
  • Rate: Calculated based on degree of dehydration + maintenance + ongoing losses
  • Add potassium chloride (KCl) if hypokalemic

• Maropitant (Cerenia): 1 mg/kg SC/IV q24h or 2 mg/kg PO q24h — NK1 receptor antagonist; highly effective, first choice
• Metoclopramide: 0.2–0.5 mg/kg PO/SC/IV q8h — prokinetic + anti-emetic
• Ondansetron: 0.1–0.2 mg/kg IV/PO q8–12h — for refractory vomiting

• Kaolin-Pectin or Bismuth subsalicylate — adsorbent; mild anti-diarrheal
• Sucralfate: 0.5–1 g PO q8h — intestinal mucosal protectant
• Omeprazole/Famotidine — if gastric ulceration/hemorrhage suspected
• Metronidazole (Flagyl): 15 mg/kg PO q12h — anti-protozoal + anti-anaerobic; often used to reduce pathogenic bacteria and improve mucosal barrier; also has immune modulatory effect in the gut
• Probiotics: Enterococcus faecium SF68, Lactobacillus acidophilus — help restore normal gut flora; useful during and after antibiotic use

• NOT indicated for uncomplicated viral CCoV (antibiotics don't kill viruses)
• Indicated when:
  • Secondary bacterial infection suspected (bloody diarrhea, fever, neutropenia)
  • Immunocompromised dogs
  • Severe enteritis with mucosal barrier breakdown (risk of bacterial translocation into bloodstream — bacteremia)
• Antibiotics used: Amoxicillin-clavulanate, Enrofloxacin, Metronidazole, or combinations

• No licensed antiviral for CCoV exists in dogs
• Treatment remains purely supportive and symptomatic

---

Treatment for Pantropic CCoV (Severe/Systemic Form)

• Aggressive IV fluid therapy — large volumes to combat shock and dehydration
• Blood/plasma transfusions — for DIC management and anemia
• Broad-spectrum antibiotics IV — prevent bacterial translocation/sepsis
• Oxygen supplementation — if respiratory involvement (interstitial pneumonia)
• Anti-convulsants (phenobarbital, diazepam) — if seizures from CNS involvement
• Intensive nursing care — keep warm, clean, encourage eating when stable
• Prognosis is guarded to poor even with aggressive treatment

---

Treatment for CRCoV (Respiratory Form)

• Rest, isolation from other dogs
• Cough suppressants (butorphanol) if severe cough
• Antibiotics for secondary bacterial co-infections (doxycycline first-line)
• Anti-inflammatories (NSAIDs) for fever
• Supportive nursing care
• Self-limiting in 1–2 weeks in uncomplicated cases

---

📌 SECTION 6 — PROGNOSIS

---

📌 SECTION 7 — PREVENTION & VACCINATION

CCoV Vaccine — WSAVA 2024 Classification: NOT RECOMMENDED

The CCoV vaccine is in the "not recommended" category according to WSAVA 2024 Guidelines. This is important.

1. The disease is generally mild and self-limiting in healthy dogs
2. Insufficient evidence that available vaccines prevent natural CCoV infection
3. Current vaccines do not protect against pantropic CCoV strains
4. The vaccine confers only short-duration protection
5. Vaccine-induced immunity may not prevent intestinal infection but may reduce severity

• Injectable modified live or inactivated vaccines exist in some countries
• Often combined with other vaccines
• Generally given as:
  • 2 doses 3–4 weeks apart initially
  • Annual boosters
• Even where available, clinical benefit is debated

CRCoV Vaccine

• NO licensed vaccine exists for CRCoV at this time
• Research ongoing — BCoV-based vaccines have been studied experimentally (due to genetic closeness)
• Prevention relies on:
  • Good kennel hygiene
  • Reducing crowding and stress
  • Vaccination against other CIRDC pathogens (CPIV, Bordetella) to reduce co-infection severity

General Prevention Measures (CCoV)

1. Strict hygiene in kennels/breeding facilities:
   • Prompt removal and disposal of feces
   • Disinfect with bleach (1:32), quaternary ammonium, or chlorhexidine
   • Clean food and water bowls daily
2. Quarantine of new dogs entering a facility — minimum 14 days before mixing with resident dogs
3. Separate puppies from adult dogs that may be shedding
4. Avoid high-density crowding — reduce stress, which lowers immune resistance
5. Good nutrition — well-nourished dogs resist infection more effectively
6. Reduce co-infection risk — vaccinate against CPV-2 and CDV (core vaccines) to prevent the synergistic worsening of CCoV disease

---

📌 SECTION 8 — CANINE CORONAVIRUS AND SARS-CoV-2 (COVID-19)

Can dogs get COVID-19 (SARS-CoV-2)?

• Yes — dogs can be infected with SARS-CoV-2 (COVID-19 virus), but dogs are NOT efficient spreaders of SARS-CoV-2 to humans
• Dogs typically show mild or no clinical signs after SARS-CoV-2 infection
• SARS-CoV-2 uses ACE2 receptor — dog ACE2 binds the virus less efficiently than cat, ferret, or human ACE2

Is SARS-CoV-2 related to canine CCoV or CRCoV?

• No direct relationship in terms of causing similar disease
• CCoV = Alphacoronavirus; CRCoV = Betacoronavirus Lineage A; SARS-CoV-2 = Betacoronavirus Lineage B (Sarbecovirus)
• They are from different coronavirus lineages
• The canine CCoV vaccine does NOT protect against SARS-CoV-2 and vice versa

CRCoV as a Model for Human Coronavirus Research

• CRCoV and human OC43 are so closely related (both betacoronavirus lineage A) that dogs with CRCoV have been proposed as a natural animal model for studying human respiratory coronavirus infections — particularly relevant during the COVID-19 pandemic era

---

📌 SECTION 9 — UNIQUE / NOTABLE FEATURES (Exam Favorites)

1. CCoV = Alphacoronavirus; CRCoV = Betacoronavirus — two completely different viruses, different taxonomy, different diseases
2. Coronaviridae named for "corona" (crown) — from the spike protein projections visible on EM
3. CCoV spares crypt epithelium — unlike parvovirus — this explains why CCoV is less severe and recovers faster
4. Pantropic CCoV = emerging threat — fatal multisystemic disease that looks like parvovirus clinically
5. Spike (S) protein recombination = source of new variants — high recombination rate → new CCoV strains with altered tropism
6. CCoV + CPV-2 = synergistic severity — co-infection dramatically worsens both diseases
7. CCoV vaccine = "not recommended" per WSAVA 2024 — insufficient evidence for clinical benefit
8. CRCoV = no vaccine available — prevention relies on hygiene and reducing exposure
9. CRCoV related to BCoV and HCoV-OC43 — a natural model for human betacoronavirus respiratory infections
10. Fecal-oral (CCoV) vs. Airborne (CRCoV) — completely different transmission routes despite both being coronaviruses

---

📌 QUICK REVISION SUMMARY TABLE

---

📌 COMMONLY ASKED QUESTIONS (Pet Owners & Vet Students)

---

This is one of the most important clinical questions. Key differences:

Feature	CCoV	CPV-2 (Parvovirus)
Severity	Mild–Moderate	Severe
Leukopenia	Mild or absent	Profound (WBC often < 500/µL)
Vomiting	Mild	Severe, persistent
Diarrhea	Watery, yellow, mild blood	Profuse, bloody ("tomato soup")
Fecal smell	Foul	Extremely fetid, distinctive
Dog's condition	Alert, stands	Collapsed, prostrate, very ill
Rapid test	CCoV ELISA fecal test	CPV ELISA fecal antigen test (SNAP) — widely available
PCR	CCoV RT-PCR	CPV PCR
Always test for BOTH — co-infection is common and more dangerous.

---

Absolutely not. They are completely different viruses from different coronavirus lineages:

• Canine Coronavirus (CCoV): Alphacoronavirus → causes diarrhea in dogs
• Canine Respiratory Coronavirus (CRCoV): Betacoronavirus → causes kennel cough
• SARS-CoV-2 (COVID-19): Betacoronavirus, Sarbecovirus lineage → causes COVID-19 in humans The canine coronavirus vaccine does NOT protect against COVID-19 and there is no cross-protection.

---

According to the WSAVA 2024 guidelines, the CCoV vaccine is classified as "not recommended" for pet dogs:

• The disease is usually mild and self-limiting
• Available vaccines do not clearly prevent infection or disease
• They do NOT protect against the dangerous pantropic strains Most veterinarians in countries following WSAVA guidelines do not routinely vaccinate dogs for CCoV. Focus on core vaccines (distemper, parvovirus, CAV-2) which are far more important.

---

Dogs infected with CCoV shed virus in their feces for approximately 6–9 days from the time of infection. They should be isolated from other dogs during this period. Clean all areas the dog has defecated in with dilute bleach (1:32 dilution).

---

Pantropic CCoV is an emerging variant of Canine Coronavirus Type IIa that can spread beyond the intestine into the bloodstream and all organs (liver, kidneys, brain, lungs, spleen). It causes fatal systemic disease that looks almost identical to severe parvovirus infection. It is most dangerous in puppies 4–12 weeks old. First documented in 2006 in Italy; cases reported across Europe and beyond. Diagnosis requires RT-PCR and genotyping. Current CCoV vaccines do NOT protect against it. This is why CCoV vaccination is even less useful than previously thought — the vaccine was designed for classic enteric strains.

---

Canine CCoV and CRCoV do NOT infect healthy humans. However, dogs can catch SARS-CoV-2 (COVID-19) from infected humans. Dogs with SARS-CoV-2 usually show mild or no symptoms. There is currently no reliable evidence that dogs spread SARS-CoV-2 back to humans in a meaningful way. Standard hygiene is always recommended when handling sick animals.

---

Feature	CCoV Type I	CCoV Type II
Spike protein	Similar to FCoV-I	Similar to TGEV (pig virus)
Cell culture growth	Poor	Good
Additional ORF3 gene	Yes	No
Pathogenicity	Usually mild	Mild to fatal (pantropic variants)
Recombination	Less studied	CCoV-IIb = recombinant with TGEV
Type II includes the pantropic variants responsible for fatal outbreaks.

---

CCoV destroys the villous tip cells and damages the intestinal mucosal barrier. This allows parvovirus easier access to crypt cells — the very cells it needs to replicate. Simultaneously, the immune system is fighting two pathogens at once and becomes overwhelmed. The combined damage is:

• Greater villous atrophy AND crypt destruction
• More severe intestinal barrier breakdown → bacterial translocation → septicemia
• More profound leukopenia
• Much higher mortality rates This is why vaccinating against parvovirus (a core vaccine) is critically important — it removes one of the two pathogens from the equation.

---

Because CCoV and CRCoV are enveloped viruses, they are much easier to kill than non-enveloped viruses like parvovirus. Effective disinfectants include:

• Dilute bleach (sodium hypochlorite) — 1:32 dilution (1 part bleach in 32 parts water)
• Quaternary ammonium compounds
• Chlorhexidine
• Iodophors
• 70% alcohol (ethanol or isopropyl) — kills enveloped viruses effectively Clean visible organic matter (feces, vomit) FIRST before applying disinfectant — organic matter reduces disinfectant efficacy.

---

CRCoV and bovine coronavirus (BCoV) are from the same betacoronavirus lineage and are so genetically similar that cross-species transmission likely occurred — a cattle coronavirus ancestor evolved to infect dogs. Human coronavirus OC43 (a common cold virus) is from the same group. This means:

1. Dogs may serve as a "mixing vessel" for betacoronavirus evolution
2. CRCoV-infected dogs are being studied as a natural animal model for human respiratory coronavirus infections
3. There is potential (though not proven) for bidirectional transmission events between species — important in the context of emerging disease surveillance

---

This is a kennel outbreak scenario. Steps:

1. Isolate all sick puppies immediately from healthy ones
2. Collect fecal samples from sick puppies → RT-PCR panel (test for CCoV Type I and II, CPV-2, CDV, Giardia, Salmonella, Campylobacter)
3. Necropsy any dead puppies → collect intestine, lymph nodes, spleen, liver, kidney, brain → histopathology + IHC + PCR for pantropic CCoV
4. Treat surviving sick puppies supportively (fluids, anti-emetics, bland diet, antibiotics if bacterial secondary infection)
5. Disinfect the entire premises with bleach
6. Advise the breeder on hygiene protocols, quarantine of new arrivals, and vaccination against core pathogens (especially CPV-2)

---

Yes — this is a very important connection. Both CCoV (Alphacoronavirus) and Feline Coronavirus / FIP virus (also Alphacoronavirus) belong to the same genus and are closely related. The FIP-like mutation mechanism (where a benign enteric feline coronavirus mutates to become the fatal systemic FIP virus) is analogous to how pantropic CCoV emerges from benign enteric CCoV. This parallel evolution is a fascinating and clinically important phenomenon — in both cats (FIP) and dogs (pantropic CCoV), a mild gut virus transforms into a deadly systemic disease through mutations in the spike protein and ORF3 gene.

---

• Merck/MSD Veterinary Manual — Canine Coronavirus (2024)
• WSAVA 2024 Guidelines for Vaccination of Dogs and Cats (Not Recommended classification)
• Decaro N & Buonavoglia C. Canine coronavirus: not only an enteric pathogen. Vet Clin North Am Small Anim Pract. 2011 [PMID: 22041207]
• Licitra BN, Duhamel GE, Whittaker GR. Canine enteric coronaviruses: emerging viral pathogens with distinct recombinant spike proteins. Viruses. 2014 [PMID: 25153347]
• Dong B et al. Epidemiological investigation of CCoV in Chinese dogs: Systematic review. Prev Vet Med. 2022 [PMID: 36327776]
• Reagan KL & Sykes JE. Canine Infectious Respiratory Disease. Vet Clin North Am Small Anim Pract. 2020 [PMID: 31813556]
• Szczepanski A et al. CRCoV, BCoV, HCoV-OC43: Receptors and attachment. Viruses. 2019 [PMID: 30959796]
• Yondo A et al. Predominance of CPIV and Mycoplasma in CIRDC. Pathogens. 2023 [PMID: 38003820]
• Pratelli A. Genetic evolution of CCoV. Vet Res. 2006 [PMID: 16472519]
• CDC EID — Canine Coronavirus Highly Pathogenic for Dogs (Buonavoglia et al.)
• Ohio State University College of Veterinary Medicine — CCoV Fact Sheet